| Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins R Singh, A Letai, K Sarosiek Nature reviews Molecular cell biology 20 (3), 175-193, 2019 | 2364 | 2019 |
| Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy. TN Chonghaile*, KA Sarosiek*, TT Vo, JA Ryan, A Tammareddi, ... Science (*equal contribution) 334 (6059), 1129-1133., 2011 | 701 | 2011 |
| Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition JA Burger, DA Landau, A Taylor-Weiner, I Bozic, H Zhang, K Sarosiek, ... Nature communications 7 (1), 11589, 2016 | 425 | 2016 |
| Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy J Montero, KA Sarosiek, JD DeAngelo, O Maertens, J Ryan, D Ercan, ... Cell 160 (5), 977-989, 2015 | 413 | 2015 |
| Transaminase inhibition by 2-hydroxyglutarate impairs glutamate biosynthesis and redox homeostasis in glioma SK McBrayer, JR Mayers, GJ DiNatale, DD Shi, J Khanal, AA Chakraborty, ... Cell 175 (1), 101-116. e25, 2018 | 397 | 2018 |
| Apoptotic cell death in disease—Current understanding of the NCCD 2023 I Vitale, F Pietrocola, E Guilbaud, SA Aaronson, JM Abrams, D Adam, ... Cell Death & Differentiation 30 (5), 1097-1154, 2023 | 369 | 2023 |
| Differentiation stage–specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas R Malumbres, KA Sarosiek, E Cubedo, JW Ruiz, X Jiang, RD Gascoyne, ... Blood, The Journal of the American Society of Hematology 113 (16), 3754-3764, 2009 | 344 | 2009 |
| CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer SF Johnson, C Cruz, AK Greifenberg, S Dust, DG Stover, D Chi, ... Cell reports 17 (9), 2367-2381, 2016 | 313 | 2016 |
| Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance N Johnson, SF Johnson, W Yao, YC Li, YE Choi, AJ Bernhardy, Y Wang, ... Proceedings of the National Academy of Sciences 110 (42), 17041-17046, 2013 | 298 | 2013 |
| BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response KA Sarosiek, X Chi, JA Bachman, JJ Sims, J Montero, L Patel, A Flanagan, ... Molecular cell 51 (6), 751-765, 2013 | 295 | 2013 |
| Developmental regulation of mitochondrial apoptosis by c-Myc governs age-and tissue-specific sensitivity to cancer therapeutics KA Sarosiek, C Fraser, N Muthalagu, PD Bhola, W Chang, SK McBrayer, ... Cancer cell 31 (1), 142-156, 2017 | 291 | 2017 |
| Mitochondria: gatekeepers of response to chemotherapy KA Sarosiek, TN Chonghaile, A Letai Trends in cell biology 23 (12), 612-619, 2013 | 197 | 2013 |
| PTP1B is a negative regulator of interleukin 4–induced STAT6 signaling X Lu, R Malumbres, B Shields, X Jiang, KA Sarosiek, Y Natkunam, ... Blood, The Journal of the American Society of Hematology 112 (10), 4098-4108, 2008 | 165 | 2008 |
| Targeting TBK1 to overcome resistance to cancer immunotherapy Y Sun, O Revach, S Anderson, EA Kessler, CH Wolfe, A Jenney, CE Mills, ... Nature 615 (7950), 158-167, 2023 | 147 | 2023 |
| Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH 3 mimetics–recent successes, current challenges and future promise KA Sarosiek, A Letai The FEBS journal 283 (19), 3523-3533, 2016 | 124 | 2016 |
| HSF1 phase transition mediates stress adaptation and cell fate decisions G Gaglia, R Rashid, C Yapp, GN Joshi, CG Li, SL Lindquist, KA Sarosiek, ... Nature cell biology 22 (2), 151-158, 2020 | 110 | 2020 |
| Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas KA Sarosiek, R Malumbres, H Nechushtan, AJ Gentles, E Avisar, ... Blood, The Journal of the American Society of Hematology 115 (3), 570-580, 2010 | 108 | 2010 |
| Radiation-induced cardiovascular toxicity: mechanisms, prevention, and treatment J Spetz, J Moslehi, K Sarosiek Current treatment options in cardiovascular medicine 20 (4), 31, 2018 | 107 | 2018 |
| Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in KRAS-Mutant Non–Small Cell … V Nangia, FM Siddiqui, S Caenepeel, D Timonina, SJ Bilton, N Phan, ... Cancer discovery 8 (12), 1598-1613, 2018 | 106 | 2018 |
| Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma KA Sarosiek, LE Cavallin, S Bhatt, NL Toomey, Y Natkunam, W Blasini, ... Proceedings of the National Academy of Sciences 107 (29), 13069-13074, 2010 | 105 | 2010 |
Anthony LetaiProfessor of Medicine, Dana-Farber Cancer InstituteVerified email at dfci.harvard.edu
